NCT02818699View on ClinicalTrials.gov

Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects

NACompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

September 14, 2018

Conditions
OverweightObese
Interventions
DIETARY_SUPPLEMENT

Placebo

280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks

DIETARY_SUPPLEMENT

EMIQ

280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks

Trial Locations (1)

02111

Human Nutrition Research Center on Aging at Tufts University, Boston

All Listed Sponsors
lead

Tufts University

OTHER

NCT02818699 - Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects | Biotech Hunter | Biotech Hunter